Newsfeeds - Spark Newswire

2 minute read

Legal
News

Cue Biopharma Reports Granted US Patents On Lead Clinical Program Novel Drug Product Candidate CUE-101

Today, 3:49 PM

Cue Biopharma, Inc. (NASDAQ:CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells directly within the body, announced today

CUE

1 minute read

12 Health Care Stocks Moving In Wednesday’s Pre-Market Session

By Benzinga Insights

Today, 3:49 PM

BLFS

6 minute read

The Daily Biotech Pulse: AzurRx Jumps On Data, Agios’ Regulatory Application For Mitapivat Accepted For Priority Review, FDA Nod For GlaxoSmithKline

By Shanthi Rexaline

Today, 3:49 PM

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 17)

ABBV

1 minute read

Cue Biopharma Q2 EPS $(0.33) Beats $(0.42) Estimate, Sales $2.74M Beat $1.06M Estimate

By Benzinga Newsdesk

Today, 3:49 PM

Cue Biopharma (NASDAQ:CUE) reported quarterly losses of $(0.33) per share which beat the analyst consensus estimate of $(0.42) by 21.43 percent. This is a 13.16 percent increase over losses of $(0.38) per share from the

CUE